Rushang D. Patel, MD, discusses the background to the single center experience with ruxolitinib as treatment of patients with chronic graft-versus-host disease.
Rushang D. Patel, MD, of Advent Health in Orlando, Florida, discusses the background to the single center experience with ruxolitinib (Jakafi) as treatment of patients with chronic graft-versus-host disease (GVHD).
There are a number of options in the second-line setting and beyond for chronic GVHD, but the response rates are not as good as clinicians hope. There is always room for better options, Patel says, and there have already been encouraging data for ruxolitinib in acute GVHD, which was approved by the FDA for the third-line setting.
While data from large clinical trials evaluating ruxolitinib in chronic GVHD are maturing, Patel shares his single center experience with ruxolitinib for chronic GVHD in this setting at the 2020 Transplantation & Cellular Therapy Meetings.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More